Expression of Fibronectin and Matrixmetalloproteinase-1(MMP-1) In Breast Cancer Patients in Basrah Province
Main Article Content
Keywords
Fibronectin, Matrixmetalloproteinase-1(MMP-1), Breast Cancer
Abstract
Fibronectin is an extracellular matrix protein that is expressed in almost all types of cancers and plays a crucial role in tumor growth promotion, survival and resistance to therapy. Matrix metalloproteinases (MMPs) are a family of enzymes implicated in the degradation and remodeling of extracellular matrix and in vascularization. The present study involved 82 samples including 57 patients of breast cancer and 25 as control (breast benign tumor). When the ELISA levels of MMP-1 in cancer patients were compared to its levels in benign tumor patients, it was noticed that the levels in cancer patients were significantly statistically higher than the levels in benign tumor patients. No such significance could be noticed when ELISA FN was tested. The comparison, of ELISA MMP-1 and ELISA FN in cancer patients sub-grouped according to type, stage, and grade of the tumor, shows that there are differences in the measures of central location and measures of dispersion. Results showed there was no any significant statistical difference in the presence of IHC MMP-1 and the presence of IHC FN between both groups, cancer and benign tumor patients. The IHC MMP-1 presence in cancer patients was investigated according to the characteristics of the malignancy, type, stage, and grade and no conclusive results could be elicited. Also, when the IHC FN presence in cancer patients was investigated according to the characteristics of the malignancy, type, stage, and grade, again no conclusive results could be elicited.
References
of science. Iraq.
2. Iraqi Cancer Registry (2010). Results of the Iraqi Cancer Registry 2008. Baghdad, Iraqi Cancer Registry Center, Ministry of Health, 2010.
3. Alwan, N. A and Al-Rufaee, F. L. (2010). Comparative demographic and clinicopathological study on the behavior of
mammary carcinoma in three Iraqi governorates (Baghdad, Hilla and Karbala). Journal of Factor Mededical Baghdad, 52(4), 419-423.
4. Habib OS, Al-Ali JK, Al-Wiswasi MK, et al (2007). Cancer registration in Basrah 2005: preliminary results. Asian Pac J Cancer Prev, 8, 187-90.
5. Habib, O. S., Hameed, L. A., Ajeel, N. A., AlHawaz, M. H., Al-Faddagh, Z. A., Nasr, G. N., ..& Abdul-Samad, A. A. (2016). Epidemiology of
breast cancer among females in Basrah. Asian Pacific journal of Cancer prevention, 17(sup3), 191-195.
6. Abood, R. A. (2018). Breast cancer in Basra oncology center: a clinicoepidemiological analysis. Asian Pacific Journal of Cancer Prevention: APJCP, 19(10), 2943.
7. Insua-Rodríguez, J., & Oskarsson, T. (2016). The extracellular matrix in breast cancer. Advanced drug delivery reviews, 97, 41-55.
8. To, W. S., & Midwood, K. S. (2011). Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis & tissue repair, 4(1), 1-17.
9. Jia, D., Yan, M., Wang, X., Hao, X., Liang, L., Liu, L., ... & Yao, M. (2010). Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC cancer, 10(1), 1-12.
10. Han, Z., & Lu, Z. R. (2017). Targeting fibronectin for cancer imaging and therapy. Journal of Materials Chemistry B, 5(4), 639-654.
11. Fernandez‐Garcia, B., Eiró, N., Marin, L., González‐Reyes, S., Gonzalez, L. O., Lamelas, M. L., & Vizoso, F. J. (2014). Expression and
prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology, 64(4), 512-522.
12. Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(31), 5287–5297.
https://doi.org/10.1200/JCO.2009.23.5556
13. Liu, H., Kato, Y., Erzinger, S. A., Kiriakova, G. M., Qian, Y., Palmieri, D., ... & Price, J. E. (2012). The role of MMP-1 in breast cancer
growth and metastasis to the brain in a xenograft model. BMC cancer, 12(1), 1-11.
14. Boström, P., Söderström, M., Vahlberg, T., Söderström, K. O., Roberts, P. J., Carpén, O., & Hirsimäki, P. (2011). MMP-1 expression has an independent prognostic value in breast cancer. BMC cancer, 11(1), 1-8.
15. Mannello, F. (2011). What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?. BMC medicine, 9(1), 1-7.
16. Avwioro, G. (2011). Histochemical uses of haematoxylin—a review. Jpcs.1(5), 24-34.Tas, F., Bilgin, E., Karabulut, S., Tastekin, D., & Duranyildiz, D. (2016). Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Molecular and Clinical Oncology, 4(4), 655-659.
17. Moon, P. G., Lee, J. E., Cho, Y. E., Lee, S. J., Chae, Y. S., Jung, J. H., ... & Baek, M. C. (2016). Fibronectin on circulating extracellular vesicles
as a liquid biopsy to detect breast cancer. Oncotarget, 7(26), 40189.
18. Kenny, H. A., Chiang, C. Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L., ... & Lengyel, E. (2014). Mesothelial cells promote
early ovarian cancer metastasis through fibronectin secretion. The Journal of clinical investigation, 124(10), 4614-4628.
19. Li, W., Liu, Z., Zhao, C., & Zhai, L. (2015). Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Srcrelated Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer. Oncology reports, 34(3), 1345-1352.
20. Jarrah,R.H., (2019). The Effectiveness of Matrix Metalloproteinases in Breast Cancer Progression and Metastasis . MSc. theisis University of Basrah, Collage of Science.50
21. McGowan, P. M., & Duffy, M. J. (2008). Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a
published database. Annals of oncology, 19(9), 1566-1572.
22. Decock, J., Hendrickx, W., Vanleeuw, U., Van Belle, V., Van Huffel, S., Christiaens, M. R., ... & Paridaens, R. (2008). Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC cancer, 8(1), 1-8.
23. Wang, Q. M., Lv, L., Tang, Y., Zhang, L., & Wang, L. F. (2019). MMP‑1 is overexpressed in triple‑negative breast cancer tissues and the
knockdown of MMP‑1 expression inhibits tumor cell malignant behaviors in vitro. Oncologyletters, 17(2), 1732-1740.
24. Argote Camacho, A. X., González Ramírez, A. R., Pérez Alonso, A. J., Rejón García, J. D., Olivares Urbano, M. A., Torné Poyatos, P., ... &
Núñez, M. I. (2021). Metalloproteinases 1 and 3 as potential biomarkers in breast cancer development. International Journal of Molecular Sciences, 22(16), 9012.
25. Wang, J., Ye, C., Lu, D., Chen, Y., Jia, Y., Ying, X., ... & Wang, L. (2017). Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis. Oncotarget, 8(53), 91379.
26. Mohammed, I.A. (2021). Matrix metalloproteinase-1 expression in invasive breast carcinoma and its relationship with clinicopathologic parameters.Ph.D. theisis University of Basrah, College of Science; P.35.
27. Köhrmann, A., Kammerer, U., Kapp, M., Dietl, J., & Anacker, J. (2009). Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC cancer, 9(1), 1-20.
28. Boström, P., Söderström, M., Vahlberg, T., Söderström, K. O., Roberts, P. J., Carpén, O., & Hirsimäki, P. (2011). MMP-1 expression has an independent prognostic value in breast cancer. BMC cancer, 11(1), 1-8.
29. Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS journal, 278(1), 16-27.
30. Waalkes, S., Atschekzei, F., Kramer, M. W., Hennenlotter, J., Vetter, G., Becker, J. U., ... & Serth, J. (2010). Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC cancer, 10(1), 1-6.
31. Bae, Y. K., Kim, A., Kim, M. K., Choi, J. E., Kang, S. H., & Lee, S. J. (2013). Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Human pathology, 44(10), 2028-2037.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.